Compare COPR & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | COPR | CRDF |
|---|---|---|
| Founded | 2010 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.1M | 67.1M |
| IPO Year | 2008 | 2012 |
| Metric | COPR | CRDF |
|---|---|---|
| Price | $1.18 | $0.87 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | ★ $15.38 | $6.28 |
| AVG Volume (30 Days) | 70.4K | ★ 346.5K |
| Earning Date | 12-01-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.37 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $609,174.00 | $365,993.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.62 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 49.61 |
| 52 Week Low | $1.05 | $0.71 |
| 52 Week High | $4.16 | $3.31 |
| Indicator | COPR | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 22.37 | 50.36 |
| Support Level | N/A | $0.88 |
| Resistance Level | $3.63 | $1.13 |
| Average True Range (ATR) | 0.22 | 0.07 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 12.37 | 73.92 |
Idaho Copper Corp is a USA-based company focused on exploring and developing its copper-molybdenum-silver deposit in Idaho, known as the CuMo project. The CuMo project currently consists of several federal unpatented lode mining claims and various patented mining claims. The unpatented lode mining claims and patented claims are situated in an unorganized mining district, in Boise County, Idaho, spanning Sections in Township 7N and 8N, Range 5E and 6E, Boise Meridian.
Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.